齐拉西酮和阿立哌唑治疗精神分裂症的临床疗效及安全性评价
Clinical efficacy and safety of ziprasidone and aripiprazole in the treatment of schizophrenia
ES评分 0
| DOI |
| 刊名 |
Journal of International Psychiatry
|
| 年，卷(期) |
2020, 47(4) |
| 作者 |
|
| 作者单位 |
河南科技大学第五附属医院 ;
|
| 摘要 |
目的：评价精神分裂症应用阿立哌唑和齐拉西酮治疗的临床疗效及安全性。方法：本次时间选取2018年1月-2019年10月内，对象选取精神分裂症患者90例，均根据入院顺序分组，2组各45例。采用阿立哌唑治疗控制组，采用齐拉西酮治疗实验组。比较两个组别BPRS、PANSS评分变化、疗效、安全性。结果：两个组别BPRS、PANSS评分等治疗前后组内对比发现P>0.05，说明二者表现出了明显差异；而组间对比均未表现出差异。两个组别治疗有效率（控制组88.89%VS实验组93.33%）对比未表现出差异（P>0.05）。两个组别不良反应率（控制组44.44%VS实验组22.22%）对比发现P<0.05，说明二者表现出了明显差异。结论：精神分裂症应用阿立哌唑和齐拉西酮治疗的疗效相当，但齐拉西酮安全性更高，利于患者病情恢复，值得推广研究。
|
| Abstract |
Objective: To evaluate the clinical efficacy and safety of aripiprazole and ziprasidone in the treatment of schizophrenia. Methods: from January 2018 to October 2019, 90 schizophrenic patients were selected and divided into two groups according to the order of admission, 45 in each group. Aripiprazole group and ziprasidone group were used. BPRS and PANSS scores, efficacy and safety were compared between the two groups. Results: the BPRS and PANSS scores of the two groups before and after treatment were significantly different (P > 0.05), but there was no difference between the two groups. There was no significant difference between the two groups (88.89% in control group vs 93.33% in experimental group) (P > 0.05). The adverse reaction rate of the two groups (44.44% of the control group vs 22.22% of the experimental group) was significantly different (P < 0.05). Conclusion: the curative effect of aripiprazole and ziprasidone in the treatment of schizophrenia is equal, but ziprasidone is more safe and beneficial to the recovery of patients condition, which is worth popularizing.
|
| 关键词 |
精神分裂症；阿立哌唑；齐拉西酮；临床疗效；安全性
|
| KeyWord |
schizophrenia; aripiprazole; ziprasidone; clinical efficacy; safety
|
| 基金项目 |
|
| 页码 |
718-720 |
杨白莎*.
齐拉西酮和阿立哌唑治疗精神分裂症的临床疗效及安全性评价 [J].
国际精神病学杂志.
2020; 47; (4).
718 - 720.